Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(11):1746–1752. doi: 10.1054/bjoc.2001.2145

High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance

H A Cocker 1, S M Hobbs 1, N Tiffin 2, K Pritchard-Jones 2, C R Pinkerton 2, L R Kelland 1
PMCID: PMC2363993  PMID: 11742497

Abstract

The MDM2 protein is known to be overexpressed in some sarcomas including rhabdomyosarcoma. However, the extent to which the MDM2 protein influences sensitivity to chemotherapeutic drugs is unclear. We have analysed this further using stable transfection of the mdm2 gene into 4 well-characterised human paediatric rhabdomyosarcoma cell lines. Transfection with the mdm2 gene resulted in increased levels of the MDM2 protein in all the cell lines. In 2 of the lines, SCMC and RD, the mdm2 gene caused between 2-fold and 61-fold increase in resistance to vincristine, etoposide and doxorubicin but not to cisplatin. In these lines there was an increase in expression of the mdr-1 gene which encodes P-glycoprotein, but not the mrp1 gene which encodes the multidrug resistance protein (MRP). The resistance was reversible using the MDR modulator PSC833, confirming the presence of P-glycoprotein. We conclude that MDM2 overexpression may be a mechanism by which multidrug resistance is regulated in some rhabdomyosarcomas. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: mdr-1, mdm2, resistance, P-glycoprotein, rhabdomyosarcoma

Full Text

The Full Text of this article is available as a PDF (91.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashcroft M., Vousden K. H. Regulation of p53 stability. Oncogene. 1999 Dec 13;18(53):7637–7643. doi: 10.1038/sj.onc.1203012. [DOI] [PubMed] [Google Scholar]
  2. Barrand M. A., Heppell-Parton A. C., Wright K. A., Rabbitts P. H., Twentyman P. R. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene. J Natl Cancer Inst. 1994 Jan 19;86(2):110–117. doi: 10.1093/jnci/86.2.110. [DOI] [PubMed] [Google Scholar]
  3. Bordow S. B., Haber M., Madafiglio J., Cheung B., Marshall G. M., Norris M. D. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994 Oct 1;54(19):5036–5040. [PubMed] [Google Scholar]
  4. Chan H. S., Thorner P. S., Haddad G., Ling V. Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol. 1990 Apr;8(4):689–704. doi: 10.1200/JCO.1990.8.4.689. [DOI] [PubMed] [Google Scholar]
  5. Chin K. V., Ueda K., Pastan I., Gottesman M. M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992 Jan 24;255(5043):459–462. doi: 10.1126/science.1346476. [DOI] [PubMed] [Google Scholar]
  6. Cocker H. A., Pinkerton C. R., Kelland L. R. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines. Br J Cancer. 2000 Aug;83(3):338–345. doi: 10.1054/bjoc.2000.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hobbs S., Jitrapakdee S., Wallace J. C. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem Biophys Res Commun. 1998 Nov 18;252(2):368–372. doi: 10.1006/bbrc.1998.9646. [DOI] [PubMed] [Google Scholar]
  8. Keleti J., Quezado M. M., Abaza M. M., Raffeld M., Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am J Pathol. 1996 Jul;149(1):143–151. [PMC free article] [PubMed] [Google Scholar]
  9. Kondo S., Kondo Y., Hara H., Kaakaji R., Peterson J. W., Morimura T., Takeuchi J., Barnett G. H. mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer. 1996 Oct;74(8):1263–1268. doi: 10.1038/bjc.1996.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kuttesch J. F., Parham D. M., Luo X., Meyer W. H., Bowman L., Shapiro D. N., Pappo A. S., Crist W. M., Beck W. T., Houghton P. J. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol. 1996 Mar;14(3):886–900. doi: 10.1200/JCO.1996.14.3.886. [DOI] [PubMed] [Google Scholar]
  11. Li Z. H., Zhu Y. J., Lit X. T. Wild-type p53 gene increases MDR1 gene expression but decreases drug resistance in an MDR cell line KBV200. Cancer Lett. 1997 Nov 11;119(2):177–184. doi: 10.1016/s0304-3835(97)00267-x. [DOI] [PubMed] [Google Scholar]
  12. Léveillard T., Wasylyk B. The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J Biol Chem. 1997 Dec 5;272(49):30651–30661. doi: 10.1074/jbc.272.49.30651. [DOI] [PubMed] [Google Scholar]
  13. Meddeb M., Valent A., Danglot G., Nguyen V. C., Duverger A., Fouquet F., Terrier-Lacombe M. J., Oberlin O., Bernheim A. MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenet Cell Genet. 1996;73(4):325–330. doi: 10.1159/000134368. [DOI] [PubMed] [Google Scholar]
  14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  15. Naito M., Tsuruo T. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol. 1997;40 (Suppl):S20–S24. doi: 10.1007/s002800051056. [DOI] [PubMed] [Google Scholar]
  16. Peng Y., Chen L., Li C., Lu W., Agrawal S., Chen J. Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem. 2001 Jan 10;276(9):6874–6878. doi: 10.1074/jbc.C000781200. [DOI] [PubMed] [Google Scholar]
  17. Sharp S. Y., Rowlands M. G., Jarman M., Kelland L. R. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer. 1994 Sep;70(3):409–414. doi: 10.1038/bjc.1994.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Suzuki A., Toi M., Yamamoto Y., Saji S., Muta M., Tominaga T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn J Cancer Res. 1998 Feb;89(2):221–227. doi: 10.1111/j.1349-7006.1998.tb00552.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tanner B., Hengstler J. G., Laubscher S., Meinert R., Oesch F., Weikel W., Knapstein P. G., Becker R. mdm 2 mRNA expression is associated with survival in ovarian cancer. Int J Cancer. 1997 Aug 22;74(4):438–442. doi: 10.1002/(sici)1097-0215(19970822)74:4<438::aid-ijc13>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  20. Taylor A. C., Shu L., Danks M. K., Poquette C. A., Shetty S., Thayer M. J., Houghton P. J., Harris L. C. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol. 2000 Aug;35(2):96–103. doi: 10.1002/1096-911x(200008)35:2<96::aid-mpo2>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  21. Thottassery J. V., Zambetti G. P., Arimori K., Schuetz E. G., Schuetz J. D. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11037–11042. doi: 10.1073/pnas.94.20.11037. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES